Application of Molecular Hydrogen in Early Heart Failure Development: Modulation of Microcirculation, Metabolism, Oxidative Stress, and Myocardial Status
Deryugina AV, Danilova DA, Polozova AV. · Antioxidants (Basel, Switzerland). 2025;14(12):1418.
What kind of evidence is this?
Preclinical
Controlled animal and cell study
Metabolic and lipid health
Inhaled H₂
Not reported in this record.
Not reported in this record.
Methods at a glance
rats, tissue, rat, cells used to study metabolic and lipid health.
Preclinical study; the full text reports 40 animals, with group/assay counts including n=40, n=10, n=2.
40 min
Full text reports inhaled H₂-containing gas. Detected intervention quantities or schedules: 2%, 96%, 21%, 40 min.
Inhaled molecular H₂ at 2%; oxygen co-delivery is reported.
H₂-related quantities reported in the intervention passages: 2%, 96%, 21%, 40 min. Values are not combined across different experimental arms.
Not reported in the full article — an absolute H₂ flow in mL/min could not be verified.
21% O₂ reported; total flow is absent, so O₂ flow in mL/min cannot be calculated.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, oxidative-stress and antioxidant markers, apoptosis or cell injury, histology or tissue damage
Article-reported result excerpt (24 words maximum): “Values for intact animals: M_TP—12.56 ± 0.83 perfusion units; Standard deviation—4.64 ± 0.77 perfusion units; Cv—36.92 ± 5.50%. “*”—statistically significant difference compared to intact…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. No funding statement was identified in the machine-readable full article; absence is not inferred. No explicit conflict statement was identified in the machine-readable full article; absence is not inferred.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 41462618 · DOI: 10.3390/antiox14121418
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10